| ALACT Stock | | | EUR 0.27 0.01 3.57% |
Chairman
Mr. Julien Parrou has served as Chairman of the Board and Chief Executive Officer of Groupe Concoursmania SA since January 2, 2008. He also serves as Manager of Saint Florentin Participations and Kensington Square SARL as well as Chairman of Telaxo and Compagnie de Liet Inc., among others.. He is a graduate of IAE, and holds a Masters degree of Business Administration since 2008.
| Tenure | 16 years |
| Phone | 33 9 70 46 86 40 |
| Web | https://acticor-biotech.com |
Parrou is the founder of Group Concoursmania SA. He specializes in the marketing of games and especially promotional contests since the age of 22 years. At that time, he founded the Journal of the Games, of which he was Director of Publishing. He then founded the website www.concours.fr. He was also appointed as Member of the Cercle du Marketing Direct and takes part in the Benchmark Group.
Acticor Biotech Management Efficiency
The company has return on total asset
(ROA) of
(0.6851) % which means that it has lost $0.6851 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(3.3291) %, meaning that it generated substantial loss on money invested by shareholders. Acticor Biotech's management efficiency ratios could be used to measure how well Acticor Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Acticor Biotech SAS has accumulated 2.2
M in total debt with debt to equity ratio
(D/E) of 662.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Acticor Biotech SAS has a current ratio of 1.17, suggesting that it
is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Acticor Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Acticor Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acticor Biotech SAS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acticor to invest in growth at high rates of return. When we think about Acticor Biotech's use of debt, we should always consider it together with cash and equity.
Acticor Biotech SAS, a clinical stage biopharmaceutical company, develops drugs for the treatment of acute phase of thrombotic diseases. The company was founded in 2013 and is headquartered in Paris, France. ACTIPLAY is traded on Paris Stock Exchange in France. Acticor Biotech SAS (ALACT) is traded on Euronext Paris in France and employs 25 people.
Management Performance
Acticor Biotech SAS Leadership Team
Elected by the shareholders, the Acticor Biotech's board of directors comprises two types of representatives: Acticor Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acticor. The board's role is to monitor Acticor Biotech's management team and ensure that shareholders' interests are well served. Acticor Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acticor Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilles MD, CEO Founder | |
| Patrice Coffe, Administrative and Financial Director, Member of the Board | |
| Eric Cohen, Chief Officer | |
| Julien Parrou, Chairman of the Board, Chief Executive Officer | |
| Hugues Duboscq, Director - Permanent Representative of Saint-Florentin Participations | |
| Martine MD, Scientific Founder | |
| Victoria PharmD, Head Assurance | |
| Jerome Leleu, Director | |
| PharmD Billiald, Scientific Founder | |
| Frederic Bartoli, Director - Representative of Chorus | |
| JeanLuc Riviere, Director - Representative of IXO PRIVATE EQUITY | |
| Sophie LebelBinay, Chief GM | |
| Laurie Jullien, Head Affairs | |
| Aymeric Humblot, Head Admin | |
| Yannick MD, GM Officer | |
| Kristell Lebozec, Head Devel | |
Acticor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Acticor Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to
measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to
predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.